ImaCor, Inc., the developer of the world's first and only hemodynamic transesophageal echocardiography (hTEE™) technology, today released the hTEE QuickStartTM mobile application. This app complements ImaCor's comprehensive hTEE training program and provides clinicians easy access to how-to videos, patient case reviews, and 24/7 customer support.
hTEE is a patient-centric technology, enabling physicians to directly visualize the heart to make better, faster treatment decisions for complex ICU patients. The hTEE ClariTEE® probe can be left indwelling for up to 72 hours so that clinicians can see the real-time effect on the heart of any dynamic adjustments in patient management. Cardiac, surgical critical care, and trauma thought leaders are using hTEE to optimize clinical and financial outcomes.
"hTEE technology provides critical information when ICU clinicians need it most," commented Peter Pellerito, ImaCor's President/CEO. "We developed the hTEE QuickStart app to make it even easier to use hTEE technology. Now, critical care teams can access clinical support and education anywhere on a mobile device, including right at the ICU patient bedside."
The hTEE QuickStart app runs on iPhone®, iPad® and AndroidTM devices and is available for free download at the App Store and Google playTM. The app can also be accessed from any mobile browser at http://htee.mobapp.at.
ImaCor, Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare resources.
ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™, Zura EVO™, Adaptaflex™, and ClariTEE® are trademarks of ImaCor, Inc. For more information, please visit our website at www.ImaCorInc.com.